Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 21, 2025 07:55 ET | Source: Teva Pharmaceutical Industries Ltd

Les besoins du patient au centre de toutes les priorités : pourquoi l’Europe doit agir pour protéger l’accès aux médicaments ?

AMSTERDAM, 21 févr. 2025 (GLOBE NEWSWIRE) -- Une nouvelle étude de Teva Pharmaceuticals Europe révèle que 46 % des médicaments génériques figurant sur la liste des médicaments essentiels de...
February 21, 2025 07:55 ET | Source: Teva Pharmaceutical Industries Ltd

Der Patient steht an erster Stelle: Warum Europa handeln muss, um den Zugang zu Arzneimitteln zu sichern

AMSTERDAM, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Laut einer neuen Studie von Teva Pharmaceuticals Europe werden 46 % der Generika auf der EU-Liste der kritischen Arzneimittel von nur einem Anbieter...
February 21, 2025 06:00 ET | Source: Teva Pharmaceutical Industries Ltd

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination of...
February 20, 2025 08:10 ET | Source: Teva Pharmaceutical Industries Ltd

Putting Patients First: Why Europe Must Act to Protect Access To Medicines

AMSTERDAM, Feb. 20, 2025 (GLOBE NEWSWIRE) -- New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from the EU Critical List of Medicines are supplied by only one provider....
February 18, 2025 16:30 ET | Source: Teva Pharmaceutical Industries Ltd

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)

TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a conference call and live webcast at 8 am E.T. on...
February 18, 2025 06:00 ET | Source: Teva Pharmaceutical Industries Ltd; Alvotech

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines...
January 29, 2025 07:00 ET | Source: Teva Pharmaceutical Industries Ltd

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023;AUSTEDO® - exceeding $1.6 billion in revenues, surpassing 2024 outlook;AJOVY® - global annual...
January 27, 2025 06:00 ET | Source: Teva Pharmaceutical Industries Ltd; Alvotech

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines...
January 13, 2025 22:26 ET | Source: Teva Pharmaceutical Industries Ltd

Teva gibt Zusammenarbeit zur Vermarktung des Formycon Biosimilar-Kandidaten für Eylea® (Aflibercept) in großen Teilen Europas und in Israel bekannt

Klinge Biopharma GmbH (Klinge) besitzt die exklusiven weltweiten Vermarktungsrechte für FYB203, Formycons Biosimilar-Kandidat für Eylea®1Die Vereinbarung basiert auf der bewährten und erfolgreichen...
January 13, 2025 22:26 ET | Source: Teva Pharmaceutical Industries Ltd

Teva annonce un partenariat en vue de commercialiser le candidat biosimilaire de Formycon à Eylea® (aflibercept) dans la majeure partie de l’Europe et en Israël

Klinge Biopharma GmbH (Klinge) détient les droits exclusifs de la commercialisation mondiale de FYB203, le candidat biosimilaire de Formycon, à Eylea®1L’accord repose sur la collaboration éprouvée et...